Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 22, 2013 - Issue 3
Submit an article Journal homepage
702
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluations

Radium-223 for the treatment of prostate cancer

Shaista HafeezRoyal Marsden Hospital, Sutton, [email protected]
&
Christopher ParkerRoyal Marsden Hospital, Sutton, [email protected]
Pages 379-387 | Published online: 15 Jan 2013

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Deborah Mukherji, Imane El Dika, Sally Temraz, Mohammed Haidar & Ali Shamseddine. (2014) Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223. Therapeutics and Clinical Risk Management 10, pages 373-380.
Read now
Neha Gupta, Omar Al Ustwani, Li Shen & Roberto Pili. (2014) Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. OncoTargets and Therapy 7, pages 223-234.
Read now

Articles from other publishers (11)

Ioulia Vardaki, Paul Corn, Emanuela Gentile, Jian H. Song, Namrata Madan, Anh Hoang, Nila Parikh, Leah Guerra, Yu-Chen Lee, Song-Chang Lin, Guoyu Yu, Elmer Santos, Marites P. Melancon, Patricia Troncoso, Nora Navone, Gary E. Gallick, Eleni Efstathiou, Sumit K. Subudhi, Sue-Hwa Lin, Christopher J. Logothetis & Theocharis Panaretakis. (2021) Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clinical Cancer Research 27:11, pages 3253-3264.
Crossref
Hojjat Ahmadzadehfar, Markus Essler, Kambiz Rahbar & Ali Afshar-Oromieh. (2018) Radionuclide Therapy for Bone Metastases. PET Clinics 13:4, pages 491-503.
Crossref
Eva Mercier, Daniel Velasco, Marta Cabezas, Cristina Agut & Meritxell Villalon. (2018) Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. Journal of Health Economics and Outcomes Research, pages 1-14.
Crossref
Eva Tirado, Daniel Callejo Velasco, Marta Rubio Cabezas, Cristina Moretones Agut & Meritxell Granell Villalón. (2018) Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. Journal of Health Economics and Outcomes Research 6:1, pages 1-14.
Crossref
Andrei H. Iagaru, Erik Mittra, Patrick M. Colletti & Hossein Jadvar. (2016) Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. Journal of Nuclear Medicine 57:Supplement 3, pages 19S-24S.
Crossref
Bhaskar Mukherjee, Yaser H Gholami, Uday Bhonsle, Reinhard Hentschel & Joseph Khachan. (2015) A unique alpha dosimetry technique using Gafchromic EBT3 ® film and feasibility study for an activity calibrator for alpha-emitting radiopharmaceuticals . The British Journal of Radiology 88:1056, pages 20150035.
Crossref
Y Gholami, X Zhu, R Fulton, S Meikle, G El-Fakhri & Z Kuncic. (2015) Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level. Physics in Medicine and Biology 60:15, pages 6087-6096.
Crossref
F. F. KnappJr.Jr., M. R. A. Pillai, J. A. OssoJr.Jr. & Ashutosh Dash. (2014) Re-emergence of the important role of radionuclide generators to provide diagnostic and therapeutic radionuclides to meet future research and clinical demands. Journal of Radioanalytical and Nuclear Chemistry 302:3, pages 1053-1068.
Crossref
Hossein Jadvar & David I. Quinn. (2013) Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer. Clinical Nuclear Medicine 38:12, pages 966-971.
Crossref
N Fujimoto, T Kubo, H Inatomi, H T T Bui, M Shiota, T Sho & T Matsumoto. (2013) Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation. Prostate Cancer and Prostatic Diseases 16:4, pages 336-340.
Crossref
Petros D. Grivas & Evan T. Keller. (2013) Radium-223: a new treatment option for bone-metastatic CRPC. Nature Reviews Urology 10:11, pages 630-631.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.